following a full submission assessed under the end of life process:
avelumab (Bavencio®) is accepted for use within NHSScotland.
Indication under review: in combination with axitinib for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC).
Avelumab plus axitinib, compared with a vascular endothelial growth factor (VEGF)-targeting tyrosine-kinase inhibitor (TKI), improved progression-free survival in adults with advanced RCC.
This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.
This advice takes account of views from a Patient and Clinician Engagement (PACE) meeting.
- Medicine name:
- avelumab (Bavencio)
- SMC ID:
In combination with axitinib is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC).
- Pharmaceutical company
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Date advice published
- 12 October 2020